Ixekizumab Biosimilar（Anti-CTLA-8 / IL-17a Reference Antibody） Datasheet DC Chemicals
Description Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.
Cat.No A860
Name Ixekizumab Biosimilar（Anti-CTLA-8 / IL-17a Reference Antibody）

Chemical Properties

CAS 1143503-69-8
Synonyms Ixekizumab;Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Research Grade Ixekizumab(DHH28801);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);Ixekizumab (anti-CTLA-8);LY2439821;LY2439821;LY2439821;LY2439821
pH value Corresponds to reference standard: PASS
Non-reduced CE-SDS >95%
SEC-HPLC >95%
Isoelectric Point Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality Corresponds to reference standard: PASS
Peptide mapping Corresponds to reference standard: PASS
N-terminal sequence Corresponds to reference standard: PASS

References

Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com